Related references
Note: Only part of the references are listed.GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
Messoud Ashina et al.
CEPHALALGIA (2021)
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
K. Chris Min et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies
Abimael Gonzalez-Hernandez et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2
Hans-Christoph Diener et al.
HEADACHE (2021)
Immunogenicity of biologic therapies for migraine: a review of current evidence
Joshua M. Cohen et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Development of Coronavirus Treatments Using Neutralizing Antibodies
Saman Fouladirad et al.
MICROORGANISMS (2021)
Monoclonal Antibodies as Neurological Therapeutics
Panagiotis Gklinos et al.
PHARMACEUTICALS (2021)
Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
Dulanji K. Kuruppu et al.
ADVANCES IN THERAPY (2021)
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
Konstantina Drellia et al.
CEPHALALGIA (2021)
Migraine therapeutics differentially modulate the CGRP pathway
Minoti Bhakta et al.
CEPHALALGIA (2021)
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
Egilius L. H. Spierings et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review
Peer Tfelt-Hansen et al.
CEPHALALGIA (2020)
Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier
Rodrigo Noseda et al.
CEPHALALGIA (2020)
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina et al.
CEPHALALGIA (2020)
The Headache Pipeline: Excitement and Uncertainty
Alan M. Rapoport et al.
HEADACHE (2020)
PAC1receptor blockade reduces central nociceptive activity: new approach for primary headache?
Jan Hoffmann et al.
PAIN (2020)
Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood-brain barrier
Agustin Melo-Carrillo et al.
PAIN (2020)
Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab)
Fernando Garces et al.
CELL REPORTS (2020)
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
Kristian Agmund Haanes et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms
Abimael González-Hernández et al.
CNS & Neurological Disorders-Drug Targets (2020)
The potential danger of blocking CGRP for treating migraine in CADASIL patients
Irene de Boer et al.
CEPHALALGIA (2020)
The fifth cranial nerve in headaches
J. C. A. Edvinsson et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
Virginia L. Stauffer et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Efficacy and safety of erenumab in women with a history of menstrual migraine
Jelena M. Pavlovic et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Differential medication overuse risk of novel anti-migraine therapeutics
Chonlawan Saengjaroentham et al.
BRAIN (2020)
One-year sustained efficacy of erenumab in episodic migraine Results of the STRIVE study
Peter J. Goadsby et al.
NEUROLOGY (2020)
CGRP inhibitors for migraine prophylaxis: a safety review
Eduardo Rivera-Mancilla et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review
Cecilia Rustichelli et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
Stephen Silberstein et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Wim M. Mulleners et al.
LANCET NEUROLOGY (2020)
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
Peter J. Goadsby et al.
LANCET NEUROLOGY (2020)
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Timothy R. Smith et al.
CLINICAL THERAPEUTICS (2020)
Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study
Valentina Orlando et al.
BMJ OPEN (2020)
The Increasingly Human and Profitable Monoclonal Antibody Market
Antonio L. Grilo et al.
TRENDS IN BIOTECHNOLOGY (2019)
Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats
Kirk W. Johnson et al.
CEPHALALGIA (2019)
A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females
Yang Xu et al.
CNS DRUGS (2019)
CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura
Aaron J. Schain et al.
JOURNAL OF NEUROSCIENCE (2019)
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey et al.
NATURE MEDICINE (2019)
Erenumab in chronic migraine Patient-reported outcomes in a randomized double-blind study
Richard B. Lipton et al.
NEUROLOGY (2019)
Erenumab in chronic migraine with medication overuse Subgroup analysis of a randomized trial
Stewart J. Tepper et al.
NEUROLOGY (2019)
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
Messoud Ashina et al.
CEPHALALGIA (2019)
Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries
Eloisa Rubio-Beltran et al.
CEPHALALGIA (2019)
N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance
Fabian Higel et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
Stephen D. Silberstein et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
Bianca Raffaelli et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Migraine and the trigeminovascular system-40 years and counting
Messoud Ashina et al.
LANCET NEUROLOGY (2019)
C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system
Jacob C. A. Edvinsson et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Targeting calcitonin gene-related peptide: a new era in migraine therapy
Andrew Charles et al.
LANCET (2019)
CGRP, Amylin, Immunology, and Headache Medicine
Frederick R. Taylor
HEADACHE (2019)
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide
Cristina Moldovan Loomis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
New Insights into the Regulation of CGRP-Family Receptors
Joseph J. Gingell et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
Erik Doevendans et al.
ANTIBODIES (2019)
The pharmacology and therapeutic applications of monoclonal antibodies
Maria Sofia Castelli et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Side effects associated with current and prospective antimigraine pharmacotherapies
Abimael Gonzalez-Hernandez et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Orit Cohen-Barak et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
Eloisa Rubio-Beltran et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
Christina Neuner Boyle et al.
MOLECULAR METABOLISM (2018)
Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries
Lena Ohlsson et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke et al.
NEUROLOGY (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Monoclonal Antibodies: A Review
Surjit Singh et al.
CURRENT CLINICAL PHARMACOLOGY (2018)
Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope
Arathi Kizhedath et al.
ARCHIVES OF TOXICOLOGY (2017)
The role of methysergide in migraine and cluster headache treatment worldwide - A survey in members of the International Headache Society
E. Anne MacGregor et al.
CEPHALALGIA (2017)
Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research
Todd J. Schwedt et al.
HEADACHE (2017)
The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine
Lars Edvinsson
HEADACHE (2017)
PACAP38 in human models of primary headaches
Hakan Ashina et al.
JOURNAL OF HEADACHE AND PAIN (2017)
The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
Min Hou et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Blocking CGRP in migraine patients - a review of pros and cons
Marie Deen et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors
Agustin Melo-Carrillo et al.
JOURNAL OF NEUROSCIENCE (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments
Carlos M. Villalon et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine
Christoph J. Schankin et al.
BRAIN (2016)
Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform
Ian N. Foltz et al.
IMMUNOLOGICAL REVIEWS (2016)
Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas
L. Becerra et al.
JOURNAL OF NEUROPHYSIOLOGY (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
Medication-overuse headache: risk factors, pathophysiology and management
Hans-Christoph Diener et al.
NATURE REVIEWS NEUROLOGY (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases
Abimael Gonzalez-Hernandez et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Licheng Shi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Therapeutic antibodies against CGRP or its receptor
Marcelo E. Bigal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
Richard B. Lipton et al.
HEADACHE (2015)
Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know
Stephen Silberstein et al.
HEADACHE (2015)
Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity
Sakeen W. Kashem et al.
IMMUNITY (2015)
Migraine: Multiple Processes, Complex Pathophysiology
Rami Burstein et al.
JOURNAL OF NEUROSCIENCE (2015)
Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins
Liming Liu
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
A second trigeminal CGRP receptor: function and expression of the AMY1 receptor
Christopher S. Walker et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Amylin: Pharmacology, Physiology, and Clinical Potential
Debbie L. Hay et al.
PHARMACOLOGICAL REVIEWS (2015)
Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38
Faisal Mohammad Amin et al.
BRAIN (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY
F. A. Russell et al.
PHYSIOLOGICAL REVIEWS (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Pituitary adenylate cyclase activating polypeptide and migraine
Alessandro S. Zagami et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
Eric D. Hostetler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Role of 5-HT1 receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn
Hyo-Jin Jeong et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935- and rauwolscine-sensitive receptors
Bruno A. Marichal-Cancino et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Sensitization of the Trigeminovascular Pathway: Perspective and Implications to Migraine Pathophysiology
Carolyn Bernstein et al.
JOURNAL OF CLINICAL NEUROLOGY (2012)
Diencephalic and brainstem mechanisms in migraine
Simon Akerman et al.
NATURE REVIEWS NEUROSCIENCE (2011)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008
Robert Y. Lin et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2009)
PACAP38 induces migraine-like attacks in patients with migraine without aura
Henrik Winther Schytz et al.
BRAIN (2009)
Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules
Edsel Maurice T. Salvana et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Immunotoxicity of monoclonal antibodies
Jacques Descotes
MABS (2009)
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs
Carlos M. Villalon et al.
PHARMACOLOGY & THERAPEUTICS (2009)
CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
J. Zeller et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
The blood-brain barrier in migraine treatment
L. Edvinsson et al.
CEPHALALGIA (2008)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Effect of two novel CGRP-binding compounds in a closed cranial window rat model
Louise Juhl et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers
Steffen Birk et al.
REGULATORY PEPTIDES (2007)
Bacterial and opportunistic infections during anti-TNF therapy
Anja Strangfeld et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
Cost of disorders of the brain in Europe
P Andlin-Sobocki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists
JJ Mallee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Drug therapy: Migraine - Current understanding and treatment.
PJ Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Triptans in migraine - A comparative review of pharmacology, pharmacokinetics and efficacy
P Tfelt-Hansen et al.
DRUGS (2000)
Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling
K Kuwasako et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
